HJ
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. - H Shs Stock: price and insider trades · Hong Kong
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. - H Shs: what insiders have been doing
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. - H Shs has a thin disclosure history in our data (latest filing: 24 June 2026). New filings will appear here as soon as they are published. Source: insider filings from HKEX. Past trades are no guide to future returns.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 1,638 of 26,897 companies
77.8
score / 100
Value82
Quality73
FCF yld12%
Earn yld11%
EV/EBITDA6.8x
ROE8.5%
Gross mgn81%
Net mgn11%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$5.43
Analyst consensus
Income statement
RevenueHK$1.3B
Gross profitHK$1.1B81% margin
EBITDAHK$211.8M16% margin
Net incomeHK$138.4M10.7% margin
Valuation
PER (trailing)8.5x
P/Book0.7x
Balance sheet & cash
Market capHK$1.3B
Total debtHK$161.6M
Free Cash FlowHK$150.2M
Debt / Equity11%
Profitability & ownership
ROE8.5%
ROA4.5%
% insiders85.9%
% institutions0.0%
Last declaration on 24 June 2026
About Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. - H Shs
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. is a company focused on the development and production of biopharmaceutical products based on genetics. It emphasizes innovation in the field of biological therapies and genetic medicines.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
